What impact will Trump's new tariffs have on pharma stocks?
Why is Microsoft cutting services to Israeli military units?
How will Starbucks' store closures affect its turnaround?
What caused NVIDIA's latest AI investment surge?
Why are Alberta and other regions considering nuclear energy?
How did the TikTok $14 billion US deal unfold?
What risks do Fed officials see in the housing market?
EMA Backs Amgen Drug For Rare Autoimmune Disorder
benzinga.com/news/health-care/25/09/47769016/ema-backs-amgen-drug-for-rare-autoimmune-disorder
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).
IgG4-RD is…
This story appeared on benzinga.com, 2025-09-19 17:17:10.